Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Inspection Fees Face Tough Road In Congress As PhRMA Remains Opposed

13 Feb 2012

• By Derrick Gingery

Related Content

Is Silence Golden For Brand Companies On Inspection Fees?

04 Apr 2011

Track and Trace Standards Coming Shortly, FDA Says

02 Jan 2012

Supply Chain Security Issues To Emerge During Subcommittee Hearing On PDUFA

31 Jan 2012

GOP Drug Shortage Strategy Pushes FDA Reform, Reimbursement Over Notification

13 Feb 2012

Tropical Disease Development Partnerships Want More Help From FDA

13 Feb 2012

FDA Envisions Many Regulatory Coalitions Dealing With Globalization Issues

26 Sep 2011

FDA Wants Authority To Enforce Track-And-Trace System For Drugs

19 Sep 2011

Inspection Fees For Drug, Ingredient Manufacturers Could End Up In PDUFA, Sen. Harkin Says

14 Sep 2011

Generic Facility Fee Unlikely To Be Charged Until A Few Months After GDUFA Implementation

19 Dec 2011

Related Companies

Pfizer Inc.

Additional Topics

United States Legislation Manufacturing Quality BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.